Testicular Yolk Sac Tumor Overview

Save information for later
Sign Up

Learn About Testicular Yolk Sac Tumor

What is the definition of Testicular Yolk Sac Tumor?
Testicular yolk sac tumor is a subtype of testicular cancer that most commonly occurs in the testicles of young and middle-age men. While the exact cause is not well understood, some risk factors have been determined, such as undescended testicle, abnormal testicle development, smoking, exposure to some chemicals, family history of testicular cancer, HIV infection, and Down syndrome.
What are the symptoms of Testicular Yolk Sac Tumor?
Testicular yolk sac tumor may have no symptoms or appear as a painless mass in the testes. If symptoms occur, they may include discomfort or pain, or a sense of heaviness in the scrotum, lower back of abdominal pain, an enlarged testicle, or an overgrowth of male breast tissue. The cancer may spread to other parts of the body.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Testicular Yolk Sac Tumor?
Treatment for testicular yolk sac cancer depends on how far the cancer has spread and includes surgery (removal of the testicle), radiation therapy, and chemotherapy. Testicular yolk sac cancer is highly treatable and has a high rate of success. Testicular cancer can be detected early by performing a monthly testicular self-examination.
Who are the top Testicular Yolk Sac Tumor Local Doctors?
Andrew Berchuck
Distinguished in Testicular Yolk Sac Tumor
Dr. Andrew Berchuck
Gynecologic Oncology
Distinguished in Testicular Yolk Sac Tumor
Dr. Andrew Berchuck
Gynecologic Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Berchuck is a Gynecologic Oncologist in Durham, North Carolina. Dr. Berchuck is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Tubal Ligation, and Oophorectomy. Dr. Berchuck is currently accepting new patients.

Pedro T. Ramirez
Distinguished in Testicular Yolk Sac Tumor
Dr. Pedro T. Ramirez
Gynecologic Oncology | Oncology
Distinguished in Testicular Yolk Sac Tumor
Dr. Pedro T. Ramirez
Gynecologic Oncology | Oncology

Tmh Physician Associates PLLC

6550 Fannin St, Suite 901, 
Houston, TX 
713-441-1026
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pedro Ramirez is a Gynecologic Oncologist and an Oncologist in Houston, Texas. Dr. Ramirez is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Hysterectomy, and Endoscopy. Dr. Ramirez is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Angeles Alvarez-Secord
Distinguished in Testicular Yolk Sac Tumor
Dr. Angeles Alvarez-Secord
Gynecologic Oncology
Distinguished in Testicular Yolk Sac Tumor
Dr. Angeles Alvarez-Secord
Gynecologic Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Angeles Alvarez-Secord is a Gynecologic Oncologist in Durham, North Carolina. Dr. Alvarez-Secord is rated as a Distinguished provider by MediFind in the treatment of Testicular Yolk Sac Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Hysterectomy. Dr. Alvarez-Secord is currently accepting new patients.

View All Doctors
What are the latest Testicular Yolk Sac Tumor Clinical Trials?
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-pr...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells
Enrollment Status: Recruiting
Publish Date: November 03, 2025
Intervention Type: Genetic
Study Phase: Phase 1

Summary: The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill o...

View All Clinical Trials